Drugs / ONO-1110
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06752603 | Apr 2025 → Jun 2026 | interstitial cystitis | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06752590 | Mar 2025 → May 2026 | fibromyalgia | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06708416 | Feb 2025 → May 2026 | postherpetic neuralgia | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06805565 | Jan 2025 → May 2026 | social phobia | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06792136 | Jan 2025 → Apr 2026 | major depressive disorder | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONO-1110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06752603 ↗ |